Inclusion Criteria:

1. Female ≥ 18 years of age. If female of child bearing potential and if outside of the
window of 10 days since the first day of the 0last menstrual period, patient will be
required to have a negative pregnancy test.

2. Pathologically proven invasive duct carcinoma of the breast (FNA or core biopsy),
T1-T4(T ≥ 1.5 cm)

3. FluGlucoScan Injection and 18F-FAZA PET scans performed prior to treatment.

4. FluGlucoScan Injection and 18F-FAZA PET scans performed within 4 weeks prior to their
definitive surgery if subject does not have neoadjuvant therapy.

5. Able and willing to follow instructions and comply with the protocol

6. Provide written informed consent prior to participation in the study.

7. ECOG performance score ≤ 2

Exclusion Criteria:

1. Previous malignancy or diagnosis less than ten (10) years ago. Skin Cancers
(excluding malignant melanoma) and carcinoma in situ of the cervix are exceptions.

2. Excisional biopsy of the primary breast tumour has been performed

3. Women with an invasive carcinoma of the breast that is not predominantly of the
invasive duct subtype

4. Primary breast carcinoma previously treated.

5. Women who are nursing or pregnant.